Head-to-head · WeighScore
Corsica Health vs Primary Clinic (Direct GLP)
The verdict
Primary Clinic (Direct GLP) takes it — 68.7/100 to 66.3/100.
Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Corsica Health | Primary Clinic (Direct GLP) |
|---|---|---|
| WeighScore | 66.3/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #193 | #144 |
| Semaglutide | $249/mo (compounded) | $65/mo (0.25 mg dose, promotional rate, compounded) |
| Tirzepatide | $349/mo (compounded) | $110/mo (2.5 mg dose, promotional rate, compounded) |
| Coverage | Coverage not published | 10 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #193 · C
Strengths
- Public pricing shown for both compounded and brand-name options — a real transparency advantage
- $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
- LegitScript Certified
- Clear 3-step intake: Assessment, Provider Review, Receive Medication
- $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced
Where it loses points
- Legal entity name and state of incorporation not disclosed on the site
- Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
- Per-state availability not listed publicly
- First-month promotional pricing not disclosed
- Lab-work inclusion not clearly disclosed
Graded #144 · C
Strengths
- Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- Routine labs and thousands of medications included in membership — no surprise bills
- Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
Where it loses points
- 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
- Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
- 503A pharmacy partners not named
- LegitScript certification not mentioned on the site
- Medical director and corporate legal entity not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.